Abstract:Grade 3 Pleomorphic Xanthastrocytoma is a rare tumour (less than 1% of all astrocytic glial neoplasms). Present most commonly with seizures. Surgery and Radiation remain the mainstay of treatment with no clear role for traditional systemic chemotherapies; BRAF inhibitors show some benefit. We report two cases who were diagnosed within a month of each other - one was initially diagnosed in 2017- presented with altered smell, headache and diplopia. Found to have a well-defined lobulated heterogeneously enhancing suprasellar parasellar lesion. After Gross Total Resection, was diagnosed from various centers as Anaplastic Ependymoma WHO Grade III; Gllioblastoma WHO Grade IV; Anaplastic Pleomorphic Xanthastrocytoma WHO Grade III. Based on immunohistochemistry, was considered Anaplastic Ependymoma WHO Grade III. Spine screening was negative; received adjuvant Radiation 60Gy in 30 fractions. After a disease free interval of 6 years, developed a recurrence at the post op site. He underwent repeat decompression and the histopathology showed Grade 3 Pleomorphic Xanthastrocytoma. Immunohistochemistry- OLIG2: diffuse positive; R132H p.IDH1: negative; ATRX: intact nuclear expression; Mismatch repair proteins (MSH2, MSH6, MLH1, PMS2); intact nuclear expression; MIB-1 labelling index: 10-12%; H3 p.K27M: negative; GFAP: variable positivity; Podoplanin and p53 shows focal positivity; EMA, CD 34 are negative. He competed Reirradiation in January 2024. He is asymptomatic and on follow up. The second case -15 year old boy presented with episodes of absence seizures. Imaging showed a predominantly extraaxial lesion at tentorial apex. He underwent decompression and histopathology showed Grade 3 Pleomorphic Xanthastrocytoma. Immunohistochemistry - cells positive for S100 and variably positive for GFAP, OLIG2 and vimentin; ATRX: Retained expression, IDH1p.R132H, EMA, Synaptophysin, Neu N: Negative, p53: Focally positive, CD34: Positive in few tumour cells, Ki-67: 14-16 %.V600 mutation detected in the BRAF gene. Had Adjuvant RT 60 Gy in 30 fractions -completed in March 2024. MRI at 1 month - no significant change in overall tumour burden compared to post operative MRI. Was offered Dabrafenib with Trametinib.

Pleomorphic Xanthoastrocytoma:Imaging Findings and Pathology Correlation

MRI analysis of pleomorphic xanthoastrocytoma

Pleomorphic Xanthoastrocytoma:Clinical Analysis of 8 Cases

Clinicopathological, Morphological and Molecular study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma

Clinical features of pediatric pleomorphic xanthoastrocytoma in temporal lobe

Clinicopathologic study of pleomorphic xanthoastrocytoma and giant cell glioblastoma

Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma

Pigmented Pleomorphic Xanthoastrocytoma: a Rare Variant and Literature Review.

Gemistocytic astrocytoma：correlation of CT and MRI findings and pathology

Molecular Features of Pleomorphic Xanthoastrocytoma.

The CT and MRI Appearance of Pilocytic Astrocytoma

Anaplastic Pleomorphic Xanthoastrocytoma with Disseminated Growth Pattern at the Time of Diagnosis As Well As after Treatment: Case Report and Review of Literature

Clinical Manifestations And Outcomes Of Typical Versus Atypical Pleomorphic Xanthoastrocytoma: A Single-Institution Experience

Infratentorial Pleomorphic Xanthoastrocytoma: Report Of Two Cases And Review Of Literature

Analysis of Comparative Genomic Hybridization in Pleomorphic Xanthoastrocytoma

Comparative analysis imaging manifestations between cystic oligodendroglioma and pleomorphic xanthoastrocytoma

Gliosarcoma Imaging Features and Pathologic Analysis

MRI features of pilocytic astrocytoma

MR Imaging Characteristics of Pilocytic and Pilomyxoid Astrocytomas Arising from Sellar Region in Children

Path-34. It Never Rains But It Pours - Diagnosing Anaplastic Pleomorphic Xanthastrocytoma Twice In A Fortnight - Our Experience In A Resource Constrained Setting

MRI Characteristics of Pilomyxoid Astrocytoma